UNSPSC 51102825: Benzalkonium/oxyquinoline

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE109. This VA Drug Class (DE109) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL, OTHER.

UNSPSC 51102825 Benzalkonium/oxyquinoline is a Commodity code under which state and local governments procure pharmaceutical and medical supply products, though recent activity shows significant mismatch between the code's nominal scope and actual solicitations. The issuing bodies span county health departments, state health and human services agencies, municipal fire departments, and cooperative purchasing alliances representing multiple states. Work being solicited includes naloxone and drug deactivation systems for community health programs, generic multi-source pharmaceuticals and over-the-counter products for statewide distribution through authorized wholesalers, medical and first aid supplies for emergency response divisions, and direct-to-manufacturer prescription fulfillment capabilities for pharmacy benefit programs.

Recent opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the City of Tampa's IFB 26P00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of medical and first aid supplies totaling an estimated $700,000 and designated as a sheltered market for certified Small Local Business Enterprises with a 5 percent bid discount; the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products for participating state and local facilities across Minnesota and Oregon, effective July 1, 2026; and the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs for self-insured health plans. Primary recent activity concentrates in Florida, Texas, and the Minnesota cooperative-purchasing footprint, with municipal and county health procurement driving operational spending alongside state-level framework agreements.